Author at Microdose

James Hallifax

James Hallifax is a writer and journalist who covers the psychedelic medicines space. After originally founding The Psychedelic Investor, James worked with Psychedelic Spotlight for a year, before going freelance. He now writes weekly for Microdose.buzz, and other publications.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Finance

8 May 2023

Which Psychedelic Medicine Companies Have the Best Financials?

As I have written many times before, the success or failure of a psychedelic medicine company depends heavily on its financial position....

By James Hallifax

Industry

18 Apr 2023

LSD Decreased Depression Symptoms by 50% in New MindMed Study

On April 14th, psychedelic medicine company MindMed (Nasdaq: MNMD, NEO: MMED) released preliminary data from a Phase 2 clinical trial, which attempted to treat Major Depressive Disorder (MDD) with LSD-assisted...

By James Hallifax

Industry

5 Apr 2023

Small Pharma Announces Positive 6-month Data from Phase 2a DMT Trial

Small Pharma releases additional data from its Phase 2 trial — nearly 2/3 of patients remained in remission after 6 months....

By James Hallifax

Finance

3 Apr 2023

Chrisitian Angermayer Shows Faith in Atai, Buys Another 1.2 M Shares

On March 29th, Christian Angermayer, Founder and Chairman of atai Life Sciences (Nasdaq: ATAI), announced that he was buying more shares of the psychedelic medicines and biotechnology company....

By James Hallifax

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

9 Mar 2023

Are LSD and r-MDMA the Future of Psychedelics? MindMed Says Yes

On March 8th, MindMed CEO Robert Barrow spoke for 30 minutes at the 43rd annual Cowen Healthcare Conference....

By James Hallifax

Industry

6 Mar 2023

The Importance of Cybin’s Next-Generation Psilocybin

Cybin presented data from its ongoing next-generation psilocybin clinical trial during the company’s R&D day....

By James Hallifax

Industry

23 Feb 2023

Compass Pathways’ New Psilocybin For Depression Trial, Explained

On February 17th, psychedelic medicine company Compass Pathways (Nasdaq: CMPS) registered a new Phase 2 clinical trial attempting to treat Major Depressive Disorder using psilocybin-assisted therapy....

By James Hallifax

Law & Politics

9 Feb 2023

Australia Legalizes Psychedelics: Are the US and Canada Next?

Australia has legalized psychedelic therapy, could either Canada or the USA be next to legalize medical psilocybin and MDMA?...

By James Hallifax

Law & Politics

8 Feb 2023

In Defence of Psychedelic Capitalism

While it may be correct to be concerned about psychedelic capitalism - there's no denying that there are some benefits as well....

By James Hallifax

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts

James Hallifax is a writer and journalist who covers the psychedelic medicines space. After originally founding The Psychedelic Investor, James worked with Psychedelic Spotlight for a year, before going freelance. He now writes weekly for Microdose.buzz, and other publications.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads